Britons FURIOUS at Macron after French President's scaremongering – 'Could cost lives!'

The French President launched a stunning attack on the UK’s vaccination programme and questioned the effectiveness of the jab developed by scientists at the University of Oxford. Last month, Mr Macron said the Oxford vaccine was “quasi-ineffective” on people older than the age of 65 – but just hours later European regulators approved it.

He also condemned the UK’s decision to maximise the number of first doses and extend the time for people to receive their second dose.

Now, a study by scientists in Scotland found the Oxford vaccine could reduce a person’s risk of being admitted to hospital by as much as 94 percent four weeks after the first dose.

Sir Patrick Vallance, the Government’s chief scientific adviser, said it is “clear that AstraZeneca works and it works in older people”.

The French President has since been mocked by a number of readers who let the opinions known in the comments section of an earlier story.

One reader wrote: “Macron just proved to be ‘quasi-effective’ of being president”.

A second added: “He should be made to answer why he come out with such nonsense, seen as he doesn’t have a PhD in science or virology.

“He should be made to answer he’s bizarre statements that he regularly spouts out.”

A third commented: “Macron obviously jumped the gun in anticipation but without the evidence. It certainly was an unnecessary statement by him that could cost lives in Europe.

A fourth wrote: “The EU blew it big time on this one, thank heavens we are out and free at last.”

Professor Andrew Pollard, chief investigator on the Oxford vaccine trial, said: “We are delighted to see that the real-world evidence reported today from the University of Edinburgh which confirms that both the Oxford-AstraZeneca vaccine and the Pfizer vaccine have a very substantial impact against hospitalisation with Covid-19 disease.

“Vaccines work. We now need to make sure that everyone everywhere is protected.”

Leave a Reply

Your email address will not be published.